References
- Belch J JF, McArdle B, Madhok R, et al. Decreased plasma fibrinolysis in patients with rheumatoid arthritis. Ann Rheum Dis 1984; 43: 774–7
- Byron M A, Allington M J, Chapel H M, Mowat A G, Cederholm-Williams SA. Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus. Ann Rheum Dis 1987; 46: 741–5
- Glas-Greenwalt P, Shashi Kant K, Allen C, Pollak VE. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus. J Lab Clin Med 1984; 104: 962–76
- Holland C D, Jayson M IV. Venous blood fibrinolysis and fibrinolytic potential in Raynaud's phenomenon (RP) and systemic sclerosis (SS). Ann Rheum Dis 1981; 40: 518–9
- Stratta P, Canavese C, Valmaggia P, et al. Coagulation and fibrinolysis study in systemic lupus erythematosus: haematological, urinary and tissue parameters. Thromb Haemost 1981; 46: 575–80
- Belch J JF, Madhok R, McArdle B, et al. The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double-blind study of stanazolol. Q J Med 1986; 225: 19–27
- Glas-Greenwalt P, Kant K S, Dosekun A, et al. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis. J Lab Clin Med 1985; 105: 99–107
- Rasmussen E K, Ullman S, Høier-Madsen M, Sørensen S F, Halberg P. Clinical implications of ribonucleoprotein antibody. Arch Dermatol 1987; 123: 601–5
- Jespersen J, Knudsen L H, Sidelmann J. The use of evacuated glass tubes for collection of blood samples for fibrinolytic assays. Thromb Res 1982; 25: 173–6
- Rijken D C, Wijngaards G, Welbergen J. Relationship between tissue type plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815–30
- Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemost 1979; 41: 365–83
- Jespersen J, Astrup T. A study of the fibrin plate assay of fibrinolytic agents: optimal conditions, reproducibility and precision. Haemostasis 1983; 13: 301–15
- Jespersen J, Kluft C. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen-levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator. Thromb Haemost 1985; 54: 454–9
- Kluft C. C1-inactivator-resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis. Thromb Res 1978; 13: 135–51
- Gallimore M J, Friberger P. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein-“like” activity in human plasma. Thromb Res 1982; 25: 293–8
- Jespersen J, Sidelmann J. Individual levels of plasma α2antiplasmin and α2-macroglobulin during the normal menstrual cycle and in women on oral contraceptives low in oestrogen. Thromb Haemost 1983; 50: 581–5
- Jespersen J, Kluft C. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen. Thromb Haemost 1982; 48: 283–5
- Gram J, Jespersen J. A simplified estimation of tissue plasminogen activator (t-PA) inhibition in human plasma. Fibrinolysis 1987; 1: 33–7
- Kluft C, Cooper P, Jie A FH, et al. Evaluation of euglobulin methods for the study of blood fibrinolytic activity: results for patients with rheumatoid arthritis and in the postoperative period. Haemostasis 1985; 15: 144–50
- Jespersen J. How to detect defects of tissue plasminogen activator in thrombosis-prone patients. An introduction to discussion. Fibrinolysis 1988; 2: 104–11, Suppl 2
- Krishnamurti C, Tang D B, Barr C F, Alving BM. Plasminogen activator and plasminogen activator inhibitor activities in a reference population. Am J Clin Pathol 1988; 89: 747–52
- Gitlin D, Craig J M, Janeway CA. Studies of the nature of fibrinoid in the collagen diseases. Am J Path 1957; 33: 55–65
- Kwaan H C, Astrup T. Fibrinolytic activity of reparative connective tissue. J Pathol 1964; 87: 409–14
- Kwaan H C, Astrup T. Tissue repair in presence of locally applied inhibitors of fibrinolysis. Exp Mol Pathol 1969; 11: 82–8
- Calderon J, Rodriguez-Valverde V, Sanchez Andrade S, Riestra J L, Gomez-Reyno J. Clinical profiles of patients with antibodies to nuclear ribonucleoprotein. Clin Rheumatol 1984; 3: 483–92